RESUMEN
BACKGROUND: Risk benefit strategies in managing inflammatory bowel diseases (IBD) are dependent upon understanding the risks of uncontrolled inflammation vs those of treatments. Malignancy and mortality in IBD have been associated with disease-related inflammation and immune suppression, but data are limited due to their rare occurrence. AIM: To identify and describe the most common causes of mortality, types of cancer and previous or current therapy among children and young adults with paediatric-onset IBD. METHODS: Information on paediatric-onset IBD patients diagnosed with malignancy or mortality was prospectively collected via a survey in 25 countries over a 42-month period. Patients were included if death or malignancy occurred after IBD diagnosis but before the age of 26 years. RESULTS: In total, 60 patients were identified including 43 malignancies and 26 fatal cases (9 due to cancer). Main causes of fatality were malignancies (n = 9), IBD or IBD-therapy related nonmalignant causes (n = 10; including 5 infections), and suicides (n = 3). Three cases, all fatal, of hepatosplenic T-cell lymphoma were identified, all were biologic-naïve but thiopurine-exposed. No other haematological malignancies were fatal. The 6 other fatal cancer cases included 3 colorectal adenocarcinomas and 3 cholangiocarcinomas (CCAs). Primary sclerosing cholangitis (PSC) was present in 5 (56%) fatal cancers (1 colorectal carcinoma, 3 CCAs and 1 hepatosplenic T-cell lymphoma). CONCLUSIONS: We report the largest number of paediatric-onset IBD patients with cancer and/or fatal outcomes to date. Malignancies followed by infections were the major causes of mortality. We identified PSC as a significant risk factor for cancer-associated mortality. Disease-related adenocarcinomas were a commoner cause of death than lymphomas.
Asunto(s)
Enfermedades Inflamatorias del Intestino/complicaciones , Enfermedades Inflamatorias del Intestino/mortalidad , Neoplasias/complicaciones , Neoplasias/mortalidad , Adolescente , Adulto , Edad de Inicio , Niño , Preescolar , Europa (Continente)/epidemiología , Femenino , Humanos , Lactante , Recién Nacido , Enfermedades Inflamatorias del Intestino/epidemiología , Masculino , Neoplasias/epidemiología , Estudios Prospectivos , Medición de Riesgo , Factores de Riesgo , Adulto JovenRESUMEN
Children and adolescents with Crohn's disease (CD) present often with a more complicated disease course compared to adult patients. In addition, the potential impact of CD on growth, pubertal and emotional development of patients underlines the need for a specific management strategy of pediatric-onset CD. To develop the first evidenced based and consensus driven guidelines for pediatric-onset CD an expert panel of 33 IBD specialists was formed after an open call within the European Crohn's and Colitis Organisation and the European Society of Pediatric Gastroenterolog, Hepatology and Nutrition. The aim was to base on a thorough review of existing evidence a state of the art guidance on the medical treatment and long term management of children and adolescents with CD, with individualized treatment algorithms based on a benefit-risk analysis according to different clinical scenarios. In children and adolescents who did not have finished their growth, exclusive enteral nutrition (EEN) is the induction therapy of first choice due to its excellent safety profile, preferable over corticosteroids, which are equipotential to induce remission. The majority of patients with pediatric-onset CD require immunomodulator based maintenance therapy. The experts discuss several factors potentially predictive for poor disease outcome (such as severe perianal fistulizing disease, severe stricturing/penetrating disease, severe growth retardation, panenteric disease, persistent severe disease despite adequate induction therapy), which may incite to an anti-TNF-based top down approach. These guidelines are intended to give practical (whenever possible evidence-based) answers to (pediatric) gastroenterologists who take care of children and adolescents with CD; they are not meant to be a rule or legal standard, since many different clinical scenario exist requiring treatment strategies not covered by or different from these guidelines.
Asunto(s)
Corticoesteroides/uso terapéutico , Antiinflamatorios no Esteroideos/uso terapéutico , Enfermedad de Crohn/terapia , Nutrición Enteral , Inmunosupresores/uso terapéutico , Quimioterapia de Mantención/métodos , Inducción de Remisión/métodos , Factor de Necrosis Tumoral alfa/antagonistas & inhibidores , Adalimumab , Adolescente , Corticoesteroides/efectos adversos , Algoritmos , Ácidos Aminosalicílicos/uso terapéutico , Antibacterianos/uso terapéutico , Anticuerpos Monoclonales/uso terapéutico , Anticuerpos Monoclonales Humanizados/uso terapéutico , Azatioprina/uso terapéutico , Niño , Humanos , Infliximab , Mercaptopurina/uso terapéutico , Metotrexato/uso terapéutico , Talidomida/uso terapéuticoRESUMEN
AIMS: To compare in vitro the inhibitory activity of four bacteriocin-producing Escherichia coli to a well-characterized panel of Salmonella strains, recently isolated from clinical cases in Switzerland. METHODS AND RESULTS: A panel of 68 nontyphoidal Salmonella strains was characterized by pulsed-field gel electrophoresis analysis and susceptibility to antibiotics. The majority of tested strains were genetically different, with 40% resistant to at least one antibiotic. E. coli Mcc24 showed highest in vitro activity against Salmonella (100%, microcin 24), followed by E. coli L1000 (94%, microcin B17), E. coli 53 (49%, colicin H) and E. coli 52 (21%, colicin G) as revealed using a cross-streak activity assay. CONCLUSIONS: Escherichia coli Mcc24, a genetically modified organism producing microcin 24, and E. coli L1000, a natural strain isolated from human faeces carrying the mcb-operon for microcin B17-production, were the most effective strains in inhibiting in vitro both antibiotic resistant and sensitive Salmonella isolates. SIGNIFICANCE AND IMPACT OF THE STUDY: Due to an increasing prevalence of antibiotic resistant Salmonella strains, alternative strategies to fight these foodborne pathogens are needed. E. coli L1000 appears to be a promising candidate in view of developing biotechnological alternatives to antibiotics against Salmonella infections.
Asunto(s)
Antibacterianos/biosíntesis , Antibiosis , Bacteriocinas/biosíntesis , Escherichia coli/fisiología , Salmonella/efectos de los fármacos , Antibacterianos/farmacología , Técnicas de Tipificación Bacteriana , Bacteriocinas/farmacología , Análisis por Conglomerados , Dermatoglifia del ADN , Electroforesis en Gel de Campo Pulsado , Escherichia coli/aislamiento & purificación , Escherichia coli/metabolismo , Genotipo , Humanos , Pruebas de Sensibilidad Microbiana , Salmonella/clasificación , Salmonella/crecimiento & desarrollo , Salmonella/aislamiento & purificación , Infecciones por Salmonella/microbiología , SuizaRESUMEN
Susceptibility to coeliac disease involves HLA and non-HLA-linked genes. The CTLA4/CD28 gene region encodes immune regulatory T-cell surface molecules and is a strong candidate as a susceptibility locus. We evaluated CTLA4/CD28 in coeliac disease by genetic linkage and association and combined our findings with published studies through a meta-analysis. 116 multiplex families were genotyped across CTLA4/CD28 using eight markers. The contribution of CTLA4/CD28 to coeliac disease was assessed by non-parametric linkage and association analyses. Seven studies were identified that had evaluated the relationship between CTLA4/CD28 and coeliac disease and a pooled analysis of data undertaken. In our study there was evidence for a relationship between variation in the CTLA4/CD28 region and coeliac disease by linkage and association analyses. However, the findings did not attain formal statistical significance (p = 0.004 and 0.039, respectively). Pooling findings with published results showed significant evidence for linkage (504 families) and association (940 families): p values, 0.0001 and 0.0014 at D2S2214, respectively, and 0.0008 and 0.0006 at D2S116, respectively. These findings suggest that variation in the CD28/CTLA4 gene region is a determinant of coeliac disease susceptibility. Dissecting the sequence variation underlying this relationship will depend on further analyses utilising denser sets of markers.
Asunto(s)
Antígenos de Diferenciación/genética , Antígenos CD28/genética , Enfermedad Celíaca/genética , Inmunoconjugados , Abatacept , Adolescente , Adulto , Anciano , Antígenos CD , Antígeno CTLA-4 , Enfermedad Celíaca/epidemiología , Enfermedad Celíaca/inmunología , Niño , Preescolar , Cromosomas Humanos Par 2/genética , Europa (Continente)/epidemiología , Femenino , Ligamiento Genético , Marcadores Genéticos , Predisposición Genética a la Enfermedad , Genotipo , Humanos , Lactante , Masculino , Persona de Mediana Edad , Riesgo , Estadísticas no Paramétricas , Linfocitos T/inmunologíaAsunto(s)
Enfermedad Celíaca/genética , Adolescente , Adulto , Anciano , Alelos , Niño , Preescolar , Europa (Continente) , Femenino , Genes MHC Clase II , Ligamiento Genético , Predisposición Genética a la Enfermedad , Genoma Humano , Genotipo , Antígenos HLA-DQ/genética , Humanos , Lactante , Masculino , Persona de Mediana Edad , LinajeRESUMEN
We report two children who underwent endoscopic removal of ingested foreign bodies which had perforated the stomach, one of which had migrated into the thorax.
Asunto(s)
Cuerpos Extraños/complicaciones , Estómago/lesiones , Niño , Diagnóstico Diferencial , Endoscopía Gastrointestinal/métodos , Femenino , Cuerpos Extraños/diagnóstico , Cuerpos Extraños/cirugía , Humanos , Lactante , Agujas , Estómago/cirugíaRESUMEN
BACKGROUND: Helicobacter pylori is associated with chronic gastritis and peptic ulcer in adults and in children. The purpose of the present study was to analyze the association of recurrent abdominal pain and H. pylori infection in children and to evaluate the efficacy of antimicrobial treatment in patients with evidence of infection. METHODS: The clinical and histopathologic findings in children who underwent diagnostic upper endoscopy for recurrent abdominal pain were analyzed retrospectively. Patients with evidence of infection with H. pylori were treated with a combination of omeprazole, amoxicillin, and clarithromycin. Efficacy of treatment was assessed using the 13C-urea-breath test. RESULTS: H. pylori was found in histopathologic sections of 29 (40%) of 73 patients undergoing diagnostic endoscopy for recurrent abdominal pain. Five children (17%) were of Swiss ethnic origin, and 24 (83%) were non-Swiss. All the infected patients had chronic gastritis and 4 (14%) had ulcerations in the duodenum. Treatment with omeprazole, amoxicillin, and clarithromycin resulted in eradication of the infection in all and in resolution of the clinical symptoms in 15 (80%) of 19 patients who had a follow-up examination. CONCLUSIONS: The presented data suggest that gastritis induced by H. pylori may be associated with recurrent abdominal pain and that in Switzerland infections with H. pylori primarily involve persons who are non-Swiss. A combined therapy results in eradication of the bacterium and in improvement of the clinical symptoms in a significant majority of the patients.
Asunto(s)
Dolor Abdominal/tratamiento farmacológico , Antiulcerosos/uso terapéutico , Quimioterapia Combinada/uso terapéutico , Infecciones por Helicobacter/tratamiento farmacológico , Helicobacter pylori/aislamiento & purificación , Dolor Abdominal/etnología , Adolescente , Amoxicilina/uso terapéutico , Pruebas Respiratorias , Niño , Preescolar , Claritromicina/uso terapéutico , Úlcera Duodenal/tratamiento farmacológico , Úlcera Duodenal/etnología , Úlcera Duodenal/microbiología , Endoscopía Gastrointestinal , Femenino , Gastritis/tratamiento farmacológico , Gastritis/etnología , Gastritis/microbiología , Infecciones por Helicobacter/etnología , Humanos , Masculino , Omeprazol/uso terapéutico , Recurrencia , Estudios Retrospectivos , Estómago/microbiología , Suiza/epidemiologíaRESUMEN
Hyperphenylalaninemia, which can cause neurological disorders and mental retardation, results from a mutation in phenylalanine hydroxylase or an enzyme required for biosynthesis or regeneration of its cofactor, tetrahydrobiopterin. The hyperphenylalaninemia variant primapterinuria is characterized by the excretion of 7-biopterin (primapterin). This disorder is thought to be due to a deficiency of 4a-hydroxy-tetrahydrobiopterin dehydratase (pterin-4a-carbinolamine dehydratase), but a lack of tissue activity has not been directly demonstrated. The five mutations so far recognized in patients with primapterinuria are associated with either a single amino acid change or a premature stop codon. Only C81R has been successfully expressed in soluble form, and was found to have 40% of normal activity. Tissues which could be obtained by minimally invasive procedures were analyzed for dehydratase activity. None was detected in normal human white cells or fibroblasts. However, activity was found in intestine of rat, dog, pig, and particularly humans where it was only eight times lower than in liver. Distribution along the length and across the wall of small intestine was relatively uniform. Moreover, the dehydratases from human liver and intestinal mucosa have identical kinetic properties. A biopsy of duodenal mucosa from a patient with homozygous E96K dehydratase had activity of 55 nmol. min(-1)g(-1) mucosa compared to 329 +/- 32 nmol. min(-1)g(-1) tissue in controls (n = 12). The sixfold lower tissue activity of the E96K mutant alone may not be sufficient to account for the biochemical symptoms of primapterinuria in this patient. However, accumulation of a 4a-hydroxy-tetrahydrobiopterin degradation product (a side-chain cyclic adduct), which has been observed in vitro and appears to be a dehydratase inhibitor, may further exacerbate the problem.
Asunto(s)
Biopterinas/análogos & derivados , Biopterinas/orina , Hidroliasas/genética , Hidroliasas/metabolismo , Intestino Delgado/enzimología , Mutación , Fenilcetonurias/orina , Adolescente , Animales , Biopsia , Biopterinas/metabolismo , Niño , Preescolar , Perros , Femenino , Fibroblastos/enzimología , Humanos , Lactante , Recién Nacido , Mucosa Intestinal/enzimología , Intestino Delgado/patología , Riñón/enzimología , Leucocitos/enzimología , Hígado/enzimología , Masculino , Estructura Molecular , Fenilcetonurias/patología , Polimorfismo Genético , Ratas , Piel/enzimología , PorcinosRESUMEN
Thirty HIV-infected children were cross-sectionally examined for morphologic hepatic abnormalities, using ultrasonography or histology. Abdominal ultrasonography was performed in 27 children. The liver structure was normal in four patients, one of whom had moderate symptoms of the HIV infection and three of them severe symptoms. Abnormal liver structure, compatible with hepatic steatosis, was found in 23 (85%) patients. Five of them were in an early stage of the HIV infection (category N or A), three patients were ranked in category B and 15 patients in category C. Histological examination of the liver was performed in 11 children and steatosis was documented in ten (91%). In seven (70%) of these ten children steatosis had been suspected by ultrasonography. In conclusion, steatosis is common in HIV-infected children. It is non-specific and has no impact on disease, diagnostic evaluation or management. Conclusion Ultrasonography is a sensitive, accurate, non-invasive screening tool. It is more reliable than liver function tests.
Asunto(s)
Infecciones por VIH/complicaciones , Hepatopatías/etiología , Adolescente , Biopsia , Niño , Estudios Transversales , Humanos , Hígado/diagnóstico por imagen , Hígado/patología , Hepatopatías/sangre , Hepatopatías/diagnóstico por imagen , Pruebas de Función Hepática , Estudios Retrospectivos , UltrasonografíaRESUMEN
Susceptibility to coeliac disease is genetically determined by possession of specific HLA-DQ alleles, acting in concert with one or more non-HLA linked genes. The pattern of risk seen in sibs and twins in coeliac disease is most parsimonious with a multiplicative model for the interaction between the two classes of genes. Based on a sib recurrence risk for coeliac disease of 10% and a population prevalence of 0.0033, the sib relative risk is 30. To evaluate the contribution of the MHC region to the familial risk of coeliac disease, we have examined haplotype sharing probabilities across this region in 55 coeliac disease families. Based on these probabilities the sib relative risk of coeliac disease associated with the MHC region is 3.7. Combining these results with published data on allele sharing at HLA, the estimated sib relative risk associated with the MHC region is 3.3. Therefore, the MHC genes contribute no more than 40% of the sib familial risk of coeliac disease and the non-HLA linked gene (or genes) are likely to be the stronger determinant of coeliac disease susceptibility.
Asunto(s)
Enfermedad Celíaca/genética , Complejo Mayor de Histocompatibilidad , Femenino , Antígenos HLA/genética , Haplotipos , Humanos , Escala de Lod , Masculino , Medición de RiesgoAsunto(s)
Gastritis/tratamiento farmacológico , Gastritis/microbiología , Infecciones por Helicobacter/tratamiento farmacológico , Adolescente , Amoxicilina/uso terapéutico , Antibacterianos/uso terapéutico , Antiulcerosos/uso terapéutico , Claritromicina/uso terapéutico , Granulocitos/patología , Helicobacter/aislamiento & purificación , Humanos , Masculino , Omeprazol/uso terapéutico , Penicilinas/uso terapéuticoRESUMEN
Gastrooesophageal reflux is a common clinical condition in infancy and childhood. Evaluation and treatment are indicated if it is associated with complications such as failure to thrive, oesophagitis or pulmonary symptoms. Depending on the clinical symptoms, investigations may include pH-monitoring, upper gastrointestinal series and endoscopy. Gastrooesophageal reflux may be treated by parental reassurance, dietary advice, positional treatment, prokinetic agents and acid secretion inhibitors. Surgery is rarely indicated.
Asunto(s)
Reflujo Gastroesofágico/diagnóstico , Niño , Preescolar , Terapia Combinada , Femenino , Determinación de la Acidez Gástrica , Reflujo Gastroesofágico/etiología , Reflujo Gastroesofágico/terapia , Humanos , Lactante , Masculino , PronósticoRESUMEN
A 16-year-old girl is described with abetalipoproteinaemia who underwent liver transplantation for hepatic cirrhosis. After this procedure her serum lipoprotein profile was corrected; however, fat malabsorption and steatorrhea persisted because the primary defect, a mutant microsomal triglyceride-transfer protein, remains expressed in the intestine.
Asunto(s)
Abetalipoproteinemia/complicaciones , Cirrosis Hepática/etiología , Trasplante de Hígado , Abetalipoproteinemia/metabolismo , Abetalipoproteinemia/cirugía , Adolescente , Proteínas Portadoras/metabolismo , Femenino , Humanos , Mucosa Intestinal/metabolismo , Cirrosis Hepática/cirugíaRESUMEN
UNLABELLED: We describe two siblings (female and male) with progressive tubulo-interstitial nephropathy and cholestatic liver disease. The main characteristics were progressive renal failure and elevated liver enzymes (AST, ALT and gamma-GT). Dialysis was started at the age of 1.9 and 6.5 years, respectively. Renal histology disclosed sclerosed glomeruli and atrophic tubules; the interstitium was fibrotic and infiltrated by lymphocytes. Endoscopic retrograde cholangiopancreatography revealed segmental irregularities and narrowing of the intrahepatic bile ducts, consistent with early primary sclerosing cholangitis. Liver histology showed enlarged portal triads, mild proliferation and inflammation of bile ducts, and fibrosis. At 5.9 years the girl underwent a successful renal transplantation whereas the boy is still on dialysis. CONCLUSION: The association of progressive tubulointerstitial nephropathy and cholestatic liver disease, consistent with early primary sclerosing cholangitis, constitutes a distinct autosomal recessive entity.